Stem Cells Flashcards

(34 cards)

1
Q

What are the key characteristics of stem cells

A

Self renew (Highly proliferative)
Differentiate into specialised cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the process of cell differentiation

A

The process by which stem cell becomes specialised due to changes in gene expression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Define the levels of stem cell potency

A

Totipotent: All cell types including embryonic support cells.
Pluripotent: Nearly all cells, excluding embryonic support cells.
Multipotent: Multiple, but limited cell types.
Bipotent: Two specific cell types.
Unipotent: One specific cell type.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Where are embryonic stem cells sourced from?

A

The inner cell mass of the blastocyst

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the 3 germ layers formed during gastrulation?

A

Ectoderm: skin, brain, nervous system
Mesoderm: muscles, circulatory system
Endoderm: Gut lining, internal organs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Explain the advantages of ESCs in research

A

High self renewal capacity and pluripotency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the disadvantages of ESCs?

A

Immune rejection and ethical issues relating to the destruction of an embryo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What cell types do MSCs definitely differentiate in to?

A

Adipocytes
Chondrocytes
Osteoblasts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What niche do hematopoietic stem cells occupy?

A

Vascular regions of bone marrow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Where are mesenchymal stem cells found?

A

Stromal regions of bone marrow and other tissues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How are iPSCs created

A

By reprogramming adult somatic cells (e.g. from skin or peripheral blood) using Yamanaka factors to induce pluripotency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the Yamanaka factors

A

Oct 4
Sox
Klf4
c-Myc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How are iPSCs made

A
  1. Selection of cell source
  2. Reprogramming into iPSCs
  3. Gene editing (correct mutations etc.)
  4. Culture and expansion
  5. Characterisation and quality control
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

List the advantages of using iPSCs

A

Pluripotent
Highly proliferative
Can be autologous

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

List some disadvantages of iPSCs

A

Safety concerns (teratoma risk)
Expensive
Technically complex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Explain the purpose Geron’s spinal cord trial

A

hES cell–derived oligodendrocyte progenitor cells for remyelination and nerve growth-stimulation.

17
Q

What were the reasons for the Geron trial stopping?

A

Purity/ predictability concerns
Teratoma fears (but were cysts)
Finances - ran out of money :(

18
Q

Explain a use of MSCs in clinical trials

A

ixmyelocel-T: Autologous MSC product tested for ischemic heart disease

19
Q

Which factors negatively affect the validity of MSC-based therapy

A

Donor variance
In vitro expansion
Immunogenicity
Senescence
Cryopreservation

20
Q

What are 2 ways MCSs are useful in tissue engineering

A

Tissue regeneration
Paracrine functions

21
Q

What are the paracrine functions of MSCs

A

Reduce inflammation (anti-inflammatory factors)
Modulate immune cells
Fight apoptosis and fibrosis
Improve angiogenesis
Regenerate tissue

22
Q

How are hemopoietic stem cells used to treat lymphoma/ leukemia

A

Collect donor cells via peripheral blood stem cell collection or bone marrow donation.
Patient receives high dose chemo to kill cancer cells and weaken the immune system (prevents rejection)
Inject donor cells into patient which travel to the bone marrow.

23
Q

What are some applications of iPSCs in regenerative medicine

A

Retinal pigment epithelial cells: macular degeneration
Dopaminergic neurons: To replace lost cells and restore motor function in Parkinson’s disease.
Cardiomyocytes: Integrate into cardiac tissue to restore heart function.

24
Q

What is a teratoma and why is this a concern for iPSCs?

A

Benign cancer which can damage surrounding tissue and has the potential to become malignant. This is due to genomic instability due to induced pluripotency.

25
What characteristics do cancer cells and iPSCs share
Highly proliferative Resistant to senescence Rapid cell growth/ proliferation
26
Describe some ways to reduce stem cell tumorigenicity
Sorting: Remove left over pluripotent stem cells after differentiation Stem cell suicide gene: Add genes to hPSCs. After differentiation a chemical will kill all cells with a suicide gene. Stem cell killing agents: After differentiation semi-pure progenitor cells are exposed to stemotoxic agents Stem cells without tumorigenicity
27
What contributes to iPSC immunogenicity?
Mitochondrial DNA mutations, time in culture, and cell type antigens, location of transplant site.
28
List some other challenges of stem cells in medicine
Keeping track of cells once injected. Demonstrating effectiveness. Commercial challenges
29
Compare ESCs and tissue stem cells by differentiation capacity.
ESCs are pluripotent, while tissue stem cells are multipotent.
30
What makes MSCs safer than iPSCs?
Lower tumorigenicity due to limited potency and absence of reprogramming genes.
31
Why is the eye an advantageous site for stem cell therapy?
It's immune privileged, reducing risk of rejection.
32
What was the outcome of the hESC trial for retinal diseases?
Signs of vision improvement, no serious complications, but small sample size.
33
How does CRISPR assist in iPSC therapy?
Enables correction of mutations or enhancement of cell function.
34
What is the significance of the ISCT criteria (2006)?
Standardized definition and criteria for MSCs in clinical applications.